Q2 Earnings Estimate for Medtronic Issued By Leerink Partnrs

Key Points

• Research analysts at Leerink Partnrs have cut their Q2 2026 EPS estimate for Medtronic to $1.31 per share, down from the previous forecast of $1.32.
• Medtronic recently reported a quarterly earnings of $1.26 EPS, exceeding the consensus estimate of $1.23, with revenues of $8.58 billion for the quarter.
• The company declared a quarterly dividend of $0.71 per share, representing an annualized dividend yield of 3.0%, to be paid on October 17th, 2023.

Medtronic PLC (NYSE:MDT - Free Report) - Research analysts at Leerink Partnrs cut their Q2 2026 EPS estimates for shares of Medtronic in a note issued to investors on Wednesday, August 20th. Leerink Partnrs analyst M. Kratky now anticipates that the medical technology company will earn $1.31 per share for the quarter, down from their previous forecast of $1.32. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Medtronic's current full-year earnings is $5.46 per share. Leerink Partnrs also issued estimates for Medtronic's Q3 2026 earnings at $1.37 EPS, Q4 2026 earnings at $1.70 EPS and FY2027 earnings at $6.03 EPS.

Several other equities analysts have also recently issued reports on MDT. BTIG Research reissued a "neutral" rating on shares of Medtronic in a research note on Friday, July 11th. Sanford C. Bernstein lifted their price target on shares of Medtronic from $97.00 to $98.00 and gave the company an "outperform" rating in a report on Wednesday. Royal Bank Of Canada reduced their price objective on shares of Medtronic from $105.00 to $101.00 and set an "outperform" rating on the stock in a research report on Thursday, May 22nd. Morgan Stanley reaffirmed an "overweight" rating and issued a $107.00 target price (up from $98.00) on shares of Medtronic in a research report on Tuesday, July 15th. Finally, Wall Street Zen lowered shares of Medtronic from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $100.54.

Medtronic Stock Up 3.6%

Shares of NYSE:MDT opened at $93.1320 on Thursday. Medtronic has a 1 year low of $79.29 and a 1 year high of $96.25. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.85 and a quick ratio of 1.42. The stock's 50-day moving average is $89.57 and its 200 day moving average is $88.02. The company has a market cap of $119.38 billion, a PE ratio of 25.66, a P/E/G ratio of 2.33 and a beta of 0.80.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.23 by $0.03. The firm had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.56%. The company's quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS.

Hedge Funds Weigh In On Medtronic

Large investors have recently modified their holdings of the stock. Burkett Financial Services LLC increased its stake in Medtronic by 185.0% during the 1st quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company's stock valued at $26,000 after purchasing an additional 185 shares in the last quarter. 1248 Management LLC bought a new stake in shares of Medtronic during the first quarter valued at approximately $26,000. Wood Tarver Financial Group LLC bought a new stake in shares of Medtronic during the fourth quarter valued at approximately $27,000. Delos Wealth Advisors LLC bought a new stake in shares of Medtronic during the second quarter valued at approximately $27,000. Finally, Columbia River Financial Group LLC bought a new position in Medtronic in the 1st quarter valued at approximately $28,000. Hedge funds and other institutional investors own 82.06% of the company's stock.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, September 26th. Medtronic's dividend payout ratio is currently 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.